Topical minoxidil reported hair discoloration: a cross-sectional study


Submitted: 8 May 2023
Accepted: 16 July 2023
Published: 10 August 2023
Abstract Views: 6098
PDF: 167
HTML: 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Minoxidil is a widely utilized medication androgenic alopecia. An original investigation on its potential to cause hair darkening in treated people is lacking. We conducted an observational study using two face-validated questionnaires that dermatologists altered to assess minoxidil’s hair discolouration risk. This Saudi Arabian survey collected data in October and November 2022. One questionnaire targeted the population, while the other targeted dermatologists. Survey 1 included 453 patients, 56.7% of whom were 18-24 and mostly female. It’s interesting that 26% (n=118) detected hair greying and 14.8% (n=67) noticed other color changes. With P-values of 0.0001, longer-term minoxidil users and those with a family history of hair greying had higher hair discolouration. Dermatologists completed Survey 2 (57 participants). Nearly 60% of dermatologists have ten years of experience. 42.1% of dermatologists saw grey hair after minoxidil use. 17.5% of doctors blame minoxidil for hair graying. This observational study examined the data of over 400 patients to determine if minoxidil could cause hair discoloration. Based on the data, we hypothesize that this drug may cause hair discoloration with prolonged use and in people with a family history of hair greying.


Mundt HM, Matenaer M, Lammert A, et al. Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis. J Clin Hypertens (Greenwich). 2016;18(11):1162-1167. doi:10.1111/jch.12847 DOI: https://doi.org/10.1111/jch.12847

Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review [published correction appears in Drug Des Devel Ther. 2020 Feb 10;14:575]. Drug Des Devel Ther. 2019;13:2777-2786. Published 2019 Aug 9. doi:10.2147/DDDT.S214907

Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol. 1998;138(3):407-411. doi:10.1046/j.1365-2133.1998.02115.x DOI: https://doi.org/10.1046/j.1365-2133.1998.02115.x

Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725-1736. doi:10.1096/fj.07-099424 DOI: https://doi.org/10.1096/fj.07-099424

Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review [published correction appears in Drug Des Devel Ther. 2020 Feb 10;14:575]. Drug Des Devel Ther. 2019;13:2777-2786. Published 2019 Aug 9. doi:10.2147/DDDT.S214907 DOI: https://doi.org/10.2147/DDDT.S214907

Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737-746. doi:10.1016/j.jaad.2020.06.1009 DOI: https://doi.org/10.1016/j.jaad.2020.06.1009

Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022;33(4):1896-1906. doi:10.1080/09546634.2021.1945527 DOI: https://doi.org/10.1080/09546634.2021.1945527

Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-Label Use of Topical Minoxidil in Alopecia: A Review. Am J Clin Dermatol. 2019;20(2):237-250. doi:10.1007/s40257-018-0409-y DOI: https://doi.org/10.1007/s40257-018-0409-y

Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Int J Dermatol. 2020;59(8):1013-1019. doi:10.1111/ijd.14933 DOI: https://doi.org/10.1111/ijd.14933

yakhovitsky A, Warshavsky K, Ben Mordechai Y, Pavlotsky F, Barzilai A. Harefuah. 2020;159(1):6-10

Cranwell WC, Sinclair R. Loose anagen hair syndrome: Treatment with systemic minoxidil characterised by marked hair colour change. Australas J Dermatol. 2018;59(4):e286-e287. doi:10.1111/ajd.12812 DOI: https://doi.org/10.1111/ajd.12812

Bublin JG, Thompson DF. Drug-induced hair colour changes. J Clin Pharm Ther. 1992;17(5):297-302. doi:10.1111/j.1365-2710.1992.tb01307.x DOI: https://doi.org/10.1111/j.1365-2710.1992.tb01307.x

Yale K, Juhasz M, Atanaskova Mesinkovska N. Medication-Induced Repigmentation of Gray Hair: A Systematic Review. Skin Appendage Disord. 2020;6(1):1-10. doi:10.1159/000504414 DOI: https://doi.org/10.1159/000504414

Alhayaza, G., Hakami, A., H. AlMarzouk, L., A. Al Qurashi, A., Alghamdi, G., & Alharithy, R. (2023). Topical minoxidil reported hair discoloration: a cross-sectional study. Dermatology Reports, 16(1). https://doi.org/10.4081/dr.2023.9745

Downloads

Download data is not yet available.

Citations